ABBVIE, INC. for ABBVIE INC.
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Public Law 111-148, The Patient Protection and Affordable Care Act; Public Law 111-152, The Reconciliation Act of 2010; BPCIA (biosimilars); H.R. 3723, Viral Hepatitis Testing Act of 2013; Proposals to improve viral hepatitis screening and testing; H.R. 3204, Drug Quality & Security Act of 2013; S. 957, Drug Supply Chain Security Act; S. 621, Safe Prescribing Act of 2013; H. R. 1285, A bill to amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug;Discussions to clarify or reform the 340B program; Implementation of The Prescription Drug User Fee Act (PDUFA);
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL D BOYD | — |
| CATHERINE DRATZ FERGUSON | — |
| JOHN P. FORD | — |
| ANDREW KAPLAN | — |
| HEATHER STRAWN | — |
| ADELE R WITENSTEIN | — |
Budget/Appropriations BUD
Funding for State AIDS Drug Assistance programs under Ryan White Care Act; S. 1281, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2014; H.R. 3547, Consolidated Appropriations Act, 2014; other Labor, Health and Human Services Appropriations; H.R. 2725, Food & Drug Administration Safety Over Sequestration Act of 2013; S. 1413, FDA User Fee Protection Act of 2013; FDAs Changes Being Effected Rule
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE DRATZ FERGUSON | — |
| JOHN P. FORD | — |
| ANDREW KAPLAN | — |
| HEATHER STRAWN | — |
Medicare/Medicaid MMM
Policies to enhance patient access to medicines in Medicare; Medicare payment proposals, S. 117 / H.R. 1102, Medicare Prescription Drug Price Negotiation Act of 2013; S. 740 / H.R. 1588, Medicare Drug Savings Act of 2013; H.R. 2925, Strengthening Medicare Anti-Fraud Measures Act of 2013;
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL D BOYD | — |
| ANDREW KAPLAN | — |
| ADELE R WITENSTEIN | — |
Trade (domestic/foreign) TRD
A variety of international trade issues (TPA, TTIP, TPP)
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL D BOYD | — |
| CATHERINE DRATZ FERGUSON | — |
| ANDREW KAPLAN | — |
| HEATHER STRAWN | — |
| ADELE R WITENSTEIN | — |
Taxation/Internal Revenue Code TAX
Proposals to reform domestic and international tax structures (no bills introduced); R & D Tax Credit proposals; CFC-look through proposals;
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL D BOYD | — |
| CATHERINE DRATZ FERGUSON | — |
| JOHN P. FORD | — |
| ANDREW KAPLAN | — |
| HEATHER STRAWN | — |
| ADELE R WITENSTEIN | — |
Copyright/Patent/Trademark CPT
S. 1720, Patent Transparency and Improvements Act of 2013; H.R. 3309, Innovation Act; S. 214, Preserve Access to Affordable Generics Act of 2013; H.R. 3709, Protecting Consumer Access to Generic Drugs Act of 2013; H.R. 3116, MODDERN Cures Act of 2013; H.R. 2985, Combination Drug Development Incentive Act of 2013
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN P. FORD | — |
| ANDREW KAPLAN | — |
| HEATHER STRAWN | — |
| ADELE R WITENSTEIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.